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Abstract
Background: The delineation of genomic copy number abnormalities (CNAs) from cancer samples has been instrumental
for identification of tumor suppressor genes and oncogenes and proven useful for clinical marker detection. An increasing
number of projects have mapped CNAs using high-resolution microarray based techniques. So far, no single resource does
provide a global collection of readily accessible oncogenomic array data.
Methodology/Principal Findings: We here present arrayMap, a curated reference database and bioinformatics resource
targeting copy number profiling data in human cancer. The arrayMap database provides a platform for meta-analysis and
systems level data integration of high-resolution oncogenomic CNA data. To date, the resource incorporates more than
40,000 arrays in 224 cancer types extracted from several resources, including the NCBI’s Gene Expression Omnibus (GEO),
EBI’s ArrayExpress (AE), The Cancer Genome Atlas (TCGA), publication supplements and direct submissions. For the majority
of the included datasets, probe level and integrated visualization facilitate gene level and genome wide data review. Results
from multi-case selections can be connected to downstream data analysis and visualization tools.
Conclusions/Significance: To our knowledge, currently no data source provides an extensive collection of high resolution
oncogenomic CNA data which readily could be used for genomic feature mining, across a representative range of cancer
entities. arrayMap represents our effort for providing a long term platform for oncogenomic CNA data independent of
specific platform considerations or specific project dependence. The online database can be accessed at http//www.
arraymap.org.
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Introduction
Genomic copy number abnormalities (CNAs) are a relevant
feature in the development of basically all forms of human
malignancies [1]. Many genomic imbalances are recurrent and
display tumor-specific patterns [2,3]. It is believed that these
genomic instabilities reveal mutations in tumor suppressor genes
and oncogenes which eventually result in a clone of fully malignant
cells. Investigation of CNA hot spots (chromosomal loci frequently
involved in CNA) has proven to be an effective methodology to
identify novel cancer-causing genes [4,5]. On a systems level, CNA
data along with expression or somatic mutation data is used to
detect pathways altered in cancers and to deduce functional
relevance of pathway members [6,7]. Since many CNAs have
been attributed to specific tumor types or clinical risk profiles, in
some entities copy number profiling is employed to characterize
different biological as well as clinical subtypes with implications for
treatment and individual prognosis. Subtype-associated CNA
regions are used to predict causative genes, furthering under-
standing of biological differences and leading to discovery of new
therapeutic targets [8,9].
Throughout the last two decades, molecular-cytogenetic tech-
niques have been applied to scan genomic copy number profiles in
virtually all types of human neoplasias. For whole genome analysis,
these techniques predominantly consist of chromosomal and array
comparative genomic hybridization (CGH), including CNA
detection by cDNA and single nucleotide polymorphism (SNP)
arrays [10–12]. While chromosomal CGH has a limited spatial
resolution of several megabases, the resolution of recent array
based technologies (aCGH) is mainly limited due to cost/benefit
evaluations instead of technical obstacles. In this article, we use the
terms ‘‘array CGH’’ and ‘‘aCGH’’ for all technical variants of
whole genome copy number arrays. This includes e.g. single color
arrays for which regional copy number normalization is performed
through bioinformatics procedures applied to external references
and internal data distribution.
The flood of new insights into structural genomic changes in
health and disease has led to an increased interest in genomic data
sets in genetic and cancer research. Several systematic studies of
CNAs across many cancer types have been performed [13,14].
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These efforts attempt a more complete understanding of
functional effect of CNAs in the context of cancer.
The exponential increase of high resolution CNA datasets offers
new challenges and opportunities for large-scale genomic data
mining, data modeling and functional data integration. Several
online resources have been developed, focusing on different
aspects of data content as well as representation [6,15–19]. An
overview of some of the prominent examples is given in Table 1.
In principle, these databases facilitate access and utilization of
CNA data. However, they are limited to specific aCGH platforms
and/or single institutions as well as limited disease categories, or,
as in the cases of GEO [15] and Ensembl ArrayExpress [16],
mainly serve as raw data repositories. To the best of our
knowledge, no single data source does yet provide an extensive
collection of high resolution oncogenomic CNA data which readily
could be used for genomic feature mining, across a representative
range of cancer entities.
Here we present ‘‘arrayMap’’, a web-based reference database
for genomic copy number data sets in cancer. We have generated
a pipeline to accumulate and process oncogenomic array data into
a unified and structured format. The resource incorporates
associated histopathological and clinical information where
accessible.
So far, arrayMap contains more than 40,000 arrays on 224
cancer types from five main data sources: NCBI GEO, EBI
ArrayExpress, The Cancer Genome Atlas, publication supple-
ments and user submitted data. Samples of interest can be
browsed, visualized and analyzed via an intuitive interface.
Computational tools are provided for biostatistical data analysis
such as CNA clustering for case specific or for subset data and
basic clinical correlations. arrayMap is publicly available at www.
arraymap.org.
Results
Data Content
Our combination of both ‘‘top-down’’ (publication driven) as
well as ‘‘bottom-up’’ (array data driven) approaches allowed us to
identify a comprehensive set of accessible aCGH based cancer
CNA data sets and to estimate the ratio of accessible data of the
overall published/deposited data.
As main result of the array data driven approach, we extracted
495 series comprising of 32002 arrays, generated on 237 platforms
from NCBI’s GEO. Among those, raw data files of approximately
29000 whole genome arrays were suitable for inclusion into our
data processing pipeline. When reviewing the content of AE, we
found that the majority of AE cancer genome data sets were also
submitted to GEO. At the time of writing, 11 datasets including
712 arrays not present in GEO had been processed based on AE
specific series. Detailed information on the GEO/AE data sets is
provided in Table S1.
The top-down procedure was based on our group’s continuous
monitoring of cancer related articles utilizing genome copy
number screening approaches, as established for our ‘‘Progenetix’’
project (www.progenetix.org; [19]). The census date for the
literature based data collection was August 15 2011. At this point,
we had identified 931 articles discussing a total of 53213 genomic
cancer CNA profiles based on aCGH techniques. Of these, 8728
cases out of 199 articles so far had been extracted from publication
related sources (e.g. supplementary data tables) and annotated and
made been accessible through Progenetix. This data included
cases for which only supervised information but no probe data was
available (e.g. author annotated Golden Path or cytogenetic CNA
regions). Literature based data sets containing probe specific data
or with the respective data presented to us by the authors (640
samples) were included into our arrayMap data processing
pipeline.
The data content of arrayMap is summarized in Table 2.
Current numbers on the website will include changes based on
ongoing annotation efforts (i.e. addition of data sets, removal of
low quality arrays).
As a by-product of our data collection and annotation efforts,
we are able to provide estimates of content and trends for the
platform usage and cancer entity coverage for the majority of
published data. According to the assigned ICD-O 3 (International
Classification of Diseases for Oncology, 3rd Edition) code and
descriptive diagnostic text, breast carcinoma predominates as
single largest clinical entity with 6459 arrays. Table S2 presents
sample sets in arrayMap classified by ICD-O code.
The most widely available array CGH platforms are either
based on large insert clones (BAC/P1 arrays) or based on shorter
single-stranded DNA molecules (oligonucleotide arrays), which
may or may not include single-nucleotide polymorphism specific
probe sequences (SNP arrays). Also, although designed for gene
expression profiling, cDNA arrays were used by several labora-
tories for measuring genomic copy number changes. Although all
these platforms are considered suitable for whole genome CNA
analysis, their probe densities and other parameters can affect
specific features of the analysis results [20–23]. Table S3 lists the
general platform types and corresponding overall numbers of the
data registered in arrayMap.
Table 1. Prominent online resources of genomic data.
Name Address Platform(s) Data format Comment
GEO [15] www.ncbi.nlm.nih.gov/geo 263 raw & normalized probe signal intensity largest microarray data repository
ArrayExpress* [16] www.ebi.ac.uk/arrayexpress 16 raw & normalized probe signal intensity many duplicate data in GEO
TCGA [6] cancergenome.nih.gov 1 segmentation data raw probe data is limited to download
CanGEM** [17] www.cangem.org 38 normalized probe signal intensity including many types of microarray data
CaSNP [18] cistrome.dfci.harvard.edu/CaSNP 8 average copy number & graphic focus on SNP array data
Progenetix [19] www.progenetix.org 235 ISCN*** & golden path data from publications
Data up to 29 April, 2011.
*excluding data both in GEO and ArrayExpress.
**statistical information only including CGH, SNP and cDNA data.
***International system for human cytogenetic nomenclature.
doi:10.1371/journal.pone.0036944.t001
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In reviewing the technical platform composition, two related
trends become apparent (Figure 1). Originally developed in groups
with expertise in molecular cytogenetics and cancer genome
analysis, printed large insert clone arrays (BAC/P1) were the first
whole genome CNA screening tools with a spatial resolution
surpassing that of chromosomal CGH. Other groups re-employed
cDNA arrays, developed for expression screening, for genomic
hybridizations. However, over the last years one can observe the
overwhelming use of various industrially produced oligonucleotide
array platforms, which compensate their low single probe fidelity
through a probe density at 1–3 orders of magnitude higher than
common for BAC/P1 arrays. Another reason for the success of
oligonucleotide arrays is the integration of SNP specific probes,
which in principle allows to use of the same experiments for
genetic association studies and the evaluation of copy number
neutral loss of heterozygosity regions [12,24,25].
Data Access and Usage Scenarios
Based on our experience from the Progenetix project, a strong
emphasis was put on a user friendly data interface. Here, we
followed a ‘‘dual user type’’ scenario: Users without bioinformatics
background should be able to intuitively visualize core data
features as well as to perform standard analysis procedures, while
for bioinformaticians the formatted database content should be
accessible to use with their analysis tools of choice.
Query interface. Data browsing in arrayMap is based on
two types of query methods: search by experimental series
metadata and search by sample features.
In the series query form, users can perform various search
options by specifying (i) descriptive diagnosis text; (ii) disease
classification (ICD-O 3 code(s)); (iii) disease locus (ICD topography
code(s)); (iv) PubMed ID; (v) technique(s); (vi) series ID. For sample
specific queries, additional features are available: sample ID;
platform ID or description; and single or combined regional
CNAs. Users can input gene name(s) in ‘‘regional CAN’’ search
field. When at least two characters are entered into the field,
suggestions based on a HUGO gene list are displayed for selection.
Gene selections will be converted to genomic locations.
In the results table, associated array information is displayed. A
number of links to additional and/or outside data is provided,
according to the information available: the corresponding
PubMed entries; the original GEO/AE accession display page
for more complete information; the case and publication entries on
the Progenetix website for further analysis; and importantly the
array specific data visualization page.
Data download options. On pages resulting from sample
queries or sample data processing, users are presented with options
to download sample data based on the current queryO˜s return.
Currently, three different file types are offered: JSON files, tab
separated feature files and segments list files. These files enable
bioinformaticians to perform further analyses based on their tools
of choice. Particularly, the JSON format can be used for direct
database import (e.g. MongoDB) or can be deparsed by common
libraries (e.g. JSON.pm), or being read into web applications.
Array probe data visualization. In the array plot interface,
original plots of genomic array data sets can be searched and
visualized (Figure S1). Default threshold parameters which were
either provided with the data or assigned during the initial
visualization will be loaded. In single array visualization, the
general view of probe distribution and post-thresholding segmen-
tation results are displayed for the whole genome as well as for
each individual chromosome. If multiple arrays are retrieved, users
can select sample data for downstream analysis procedures. Figure
S2 shows the screenshot of single array visualization.
Users can segment the raw data values and re-plot the results
after revising the following parameters:
N Golden path edition, default HG18/NCBI Build 36. This is
still the commonly used version of the human reference
genome assembly. At the moment, coordinates of probes from
all platforms were remapped to HG18. For the near future, we
intend to allow for a selection of updated genome editions.
N Chromosomes to plot, default 1 to 22. Single or all
chromosomes can be selected for re-plotting. To avoid gender
bias, most platforms do not contain probes in chromosome X
and Y during the design.
N Loss/gain thresholds. Cut-offs from which a segment is
considered a genomic loss or gain. The optimum thresholds
may vary between platforms.
N Region size in kb. Sets a filter to remove CNA below (e.g.
probable noise) or above (e.g. exclude non-focal CNA) a
certain size range.
N Minimal probe numbers for segments. This parameter can be
used to limit the minimal number of probes required for a
segment to be considered (e.g. to remove aberrant segmenta-
tion due to probe level noise). Empirical examples would be
values of 2–3 for high quality BAC arrays and 6–10 for
Affymetrix SNP 6 arrays.
N Plot region. Single genomic region to be plotted, overriding the
chromosome selection above. When selected, plots with this
region will be generated for all current arrays. This is valuable
to e.g. display the CNA status and copy number transition
points for specific genes of interest (Figure S3).
Zoom-in visualization of focal CNA. Figure 2 shows the
visualization of focal genomic imbalances, e.g. to identify genes of
interest targeted by focal CNA. The whole genome view of
GSM535547 (human high grade glioma sample analyzed by
Agilent Human Genome CGH Microarray 244A) shows a small
regional deletion in chromosome 9p21. When plotting the
approximate locus of the deletion (specified as chr9:21600000-
22400000), genes, probes and chromosome bands in this zoomed
in region are shown. Two genes, MTAP and CDKN2A can be
seen as being localized in a potential homozygously deleted region.
The focal deletion of these known tumor suppressor genes [26,27]
points to their specific involvement in the glioblastoma sample
analyzed here.
Querying compound CNA. The concept of focal CNA
detection can be integrated with a global search for arrays
Table 2. aCGH data integrated in arrayMap.
Data Source Arrays Cases Series Platforms Publications
GEO 32002 25728 495 237 490
ArrayExpress 712 11 16 11
TCGA 7249 3594 19 1 *
Publication
Supplements
.4578** 4578 137
Author Submission 556 539 8 7
Data up to 29 April, 2011.
*Due to lack of publication information, there may be a small amount of
duplicate data in GEO.
**Array number may be higher than case number since reported results per
case occasionally may be based on more than one array. The number does not
include data presented both in publication supplements as well as GEO.
doi:10.1371/journal.pone.0036944.t002
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containing gene specific regional imbalances. As an example, we
demonstrate the search for arrays displaying imbalances in 4 gene
loci associated with glioblastoma: EGFR, a transmembrane
receptor and proto-oncogene [28]; PTEN, a tumor suppressor
gene [29]; ASPM, frequently overexpressed in glioblastoma
relative to normal brain tissue [30]; and CDKN2A (see above).
In the ‘‘Search Samples’’ form, the ‘‘Match (Multiptle) Regions &
Types’’ can be used to specify the genomic regions of those four
genes including the expected CNA type: for EGFR
(chr7:55054219-55242524:1), PTEN (chr10:89613175-
89718511:-1), ASPM (chr1:195319885-195382287:1) and
CDKN2A (chr9:21957751-21984490:-1), respectively. When ex-
ecuting the query, these regions were matched with the whole
database and returned cases which have imbalances overlapping
all these regions. When excluding controls and ‘‘worst quality’’
datasets, 303 out of 42421 arrays could be identified matching all
four CNA regions. In addition to glioblastoma, several other types
of cancer cases were among the results, including e.g. neuroblas-
tomas, breast carcinomas, melanomas and lung carcinomas, which
is in accordance with some previous observations [31–34]. CNA
and associated data of those cases can be processed by online tools
for further analysis and visualization (Figure S4) or downloaded for
offline processing.
Copy number profiling of selected cancer entities. One
aim of arrayMap is to allow researchers to conveniently perform
aCGH meta-analysis across different platforms. By selecting a
single or several cancer entities e.g. based on their ICD entity
codes or diagnostic keywords, users are able to generate disease
specific CNA frequency profiles or to compare profiles of different
cancer types.
As an example, we used ICD-O code 9440/3 (glioblastoma,
NOS) to query the database. 1478 arrays from 25 publications
were returned and passed to our suite of online analysis tools.
Chromosomal ideograms and histograms were generated repre-
senting the frequency of copy number aberrations identified over
the whole dataset (Figure 3A). In the overall aberration profile, the
most common genomic imbalances included whole chromosome 7
gain and chromosome 10 loss, as well as focal gains e.g. on bands
1q21 and 17q21. In our example dataset, a prominent focal
deletion hot-spot was centered around 9p21.3 (921 of 1478 arrays,
62.31%) which had been discussed previously [35]. The distribu-
tion of CNAs over the individual arrays was visualized through a
matrix plot (Figure 3B). As additional information to the frequency
histograms, this form of visualization facilitates e.g. the detection of
CNA patterns among individual arrays as well as the concordance
of individual CNAs (e.g. here the arm-level changes in chromo-
some 7 and 10).
In the matrix plot, clicking on a certain segment would open
the related view in the UCSC genome browser [36], for
detailed information related to this genomic region (SVG plot
only). The plot order of arrays can be re-sorted according to
ICD morphology, ICD topography, clinical group or PubMed
ID, which can be helpful in associating CNA patterns to
external classification categories. For the selected classification
criterium (default: ICD morphology), regional CNA frequencies
for cases matching the different values will be visualized through
a heatmap (Figure 3C); this feature is especially useful when
comparing a number of different primary classification criteria.
An Overall Genomic Copy Number Profile of Cancer
Our high quality core dataset in arrayMap was used to generate
an overall cancer copy number aberration profile based on 29,137
arrays (Figure 4). This data represented 177 cancer types
according to ICD-O 3 code, with 59 types among them contained
Figure 1. Distribution of resolutions and techniques of GEO platforms. Each point represents a genomic array. The Y axis is labeled with
probe number in log scale. The X axis denotes the time sequence of array data generation. From left to right are years from 2001 to 2011.
doi:10.1371/journal.pone.0036944.g001
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more than 50 arrays. Overall, one of the most common genomic
alteration is copy-number gain of chromosome band 8q24, which
is found in 30% of total samples. According to the COSMIC [37]
database, the most significant cancer gene in this region is MYC. It
is a well-documented oncogene codes for a transcription factor
that is believed to regulate the expression of 15% of all genes,
including genes involved in cell division, growth, and apoptosis
[38,39]. Other common imbalances observed in at least 25% of
oncogenomic arrays included gains of regions on e.g. 17q21 (29%),
1q21 (33%) and loss of regions on e.g. 8p23 (32%) and 9p21
(25%), including focal deletions of the CDKN2A/B locus
(Figure 2).
While the overall CNA frequency distribution points towards
DNA features targeted in multiple entities, this information is
insufficient for deriving molecular mechanisms associated with
specific cancer types. The genomic heterogeneity of different
neoplasias is reflected in the varying patterns of regional CNA
frequencies. Based on our core dataset, we have generated a
heatmap-style visualization of frequency profiles for all ICD-O
entities containing more than 50 arrays (Figure S5). The striking
Figure 2. Zoom-in visualization of focal CNA. (A) GSM535547 (human high grade glioma, Agilent CGH 244A) shows high quality of probe
hybridization signal. CNAs are easy to distinguish. (B) When zoom-in the whole chromosome 9, an approximately 80 MB deletion is displayed, with
two breakpoints located in p and q arm respectively. In addition, a small regional deletion in 9p21 is quite clear. Color bars in lower region of the
panel represent 848 genes located in chromosome 9. (C) Zoom in the potential homozygously deleted region in 9p21 by specifying the exact region:
chr9:21600000-22400000. The zoomed-in plot shows probes, chromosome band and two tumor suppressor genes, MTAP and CDKN2A. Gene name
and location will be given while mouse hover. They link to UCSC genome browser with additional information.
doi:10.1371/journal.pone.0036944.g002
Figure 3. Copy number profiling of glioblastoma. (A) Chromosomal ideogram and histogram showing frequency of copy number aberrations.
Percentage values corresponding to gains (yellow) and losses (blue) identified over the whole dataset. The most frequent imbalances include gain of
chromosome 7 and loss of chromosome 10, 9p21.3. (B) Matrix plot of 1478 glioblastoma cases. The Y axis represents individual samples. The
distribution of genomic copy number imbalances reveals the individual aberration patterns of glioblastoma. (C) Heatmap of regional CNA frequencies
for 1478 arrays. The intensity of green and red color components correlates to the relative gain and loss frequencies, respectively. If dataset contains
cancer subtypes, cancers with similar CNA frequency profiles will be clustered together, such that differences between subtypes will be revealed (e.g.
see Figure S4H).
doi:10.1371/journal.pone.0036944.g003
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patterning of the CNA profiles indicates the non-random
occurrence of CNAs, and should be seen as an invitation to
explore e.g. CNA similarities shared by separate histopathological
entities, as a way to transpose knowledge about pathophysiological
mechanisms.
Discussion
arrayMap was developed to facilitate the progress of oncoge-
nomic research. Our aim is to provide high-quality genomic copy
number profiles of human tumors, along with a set of tools for
accessing and analyzing CNA data. The service has been
implemented with a straightforward web interface, including
search options for CNA features and clinical annotation data. All
assembled datasets are processed into platform independent
segmentation and, for the vast majority of arrays, probe level
data files, and are presented in consistent formats. Importantly, the
direct access to precomputed probe level data plots supports a
rapid evaluation of experiments for features of interest. As a
curated database using standardized annotation schemes (e.g. ICD
classification), arrayMap facilitates the exploration of cancer type
specific CNA data, as well as the statistical association of genomic
features to clinical parameters.
arrayMap is a dynamic database that is being continuously
expanded and improved. We will review the existing and newly
published articles to update the database periodically. Over the
past decade, we have witnessed a rapidly increasing number of
aCGH publications, which gives us sufficient evidences to
anticipate that cases in our database will continue to be deposited
at a high rate. Although arrayMap is not a user driven repository,
we welcome and support users interested in using the site for yet
undisclosed data, if they agree on data sharing upon publication.
Although, in contrast to the continuous data from expression
analysis, copy number analysis explores discrete value spaces
(countable number of DNA copies, for segments defined by
genomic base positions), interpretation of the data can vary due to
different low level (e.g. signal/background correction) and higher
level (e.g. segmentation algorithms, regional or size based filtering)
procedures. In that respect, we have to emphasize that the results
of our data processing and annotation procedures are open to
scrutiny. We encourage a critical review of individual results, and
are open for suggestions regarding improved processing proce-
dures for specific platforms.
In this paper, we have provided example scenarios of using
arrayMapondifferent levels, i.e. locus centric and for entityprofiling.
We believe that systematic analyses will help researchers to discover
features which are indiscernible in individual studies, and thus bring
new insights for understanding of disease pathology and the
development of new therapeutic approaches [40–43]. We expect
that researchers will integrate arrayMap datawith their own analysis
efforts, e.g. to increase sample size or for result verification purposes.
We hope that this database will promote further evolution of
microarray data meta-analysis. ArrayMap provides access to more
than 200 tumor types, which makes it suitable for research across
cancer entities. Furthermore, normal sample controls are of vital
importance for genomic imbalances studies. ArrayMap includes
more than 3000 normal samples from healthy individuals or from
normal tissues of cancer patients. These data could be integrated as
reference dataset e.g. to account for copy number variation data
superimposed on the tumor profiling results.
In the near future, with the continuous accumulation of very
high resolution CNA data from genomic arrays and next-
generation sequencing experiments, it will become possible to
integrate these data into systems biology methods to elucidate
effects of genomic instability, and describe the results from more
perspectives. Envisioned examples would be e.g. the identification
of genes that are involved in metastasis and treatment response;
identification of chromosomal breakpoints distribution in cancer;
and modeling functional networks in cancer by systems biology
approaches.
Methods
Dataset Collection
Raw experimental data from a variety of platforms and
repositories were extracted. They were converted to an uniform
format which is suited to our reanalysis and visualization system.
After a series of parsing procedures, the called copy number data is
stored in arrayMap. The flowchart of arrayMap data collection
and analysis is as shown in Figure 5. Five main data sources are
integrated into arrayMap:
GEO/AE. For extracting appropriate data Series from GEO/
AE, two basic criteria have to be fulfilled. First, the raw data has to
be from human malignancies analyzed by BAC, cDNA, aCGH or
oligonucleotide arrays. Second, the array platform must be
genome wide, with the optional omission of the sex chromosomes.
Figure 4. The overall cancer copy number aberration profile consisted of 29137 arrays. This plot represents 177 cancer types according to
ICD-O 3 code. Percentage values in Y axis corresponding to numbers of gains (green) and losses (red) account for the whole dataset.
doi:10.1371/journal.pone.0036944.g004
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Chromosome or region specific arrays were excluded because they
were not able to reveal the whole genomic profile of the respective
cancer. Associated clinical data was extracted if available.
TCGA. Segmentation data with available clinical information
was extracted and incorporated into the database. Due to data
sharing restrictions, TCGA data is an exception in that, so far no
probe level data is incorporated into arrayMap. This exception
Figure 5. The flowchart of arrayMap data collection and analysis procedures. Publicly available raw data or segmented data was collected
from the respective data sources. Files were re-processed by distinct procedures, according to the different data types. Probe coordinates were
remapped to the most commonly encountered human reference genome assembly (NCBI Build 36/hg18). All probe specific ratios were converted to
log2 values. Thresholds for genomic gain and loss were obtained from the original publications or series annotations; if not available, empirical
thresholds were assigned. A minimum of 2 probes was required for calling a CNA segment, with higher values used on high-density arrays and/or in
cases of excessive probe level noise. Processed probe and segment information was converted to uniform formats and stored in per-sample text files,
which are accessed through the arrayMap web applications.
doi:10.1371/journal.pone.0036944.g005
arrayMap: Genomic Copy Number Imbalances Cancer
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36944
was accepted since users will be able to access individual TCGA
datasets through the projects web portal at http://tcga-data.nci.
nih.gov/tcga/.
Publications. Many aCGH datasets can be found in the text
or supplementary files of publications. In order to collect data from
publications, we relied on our Progenetix projectO˜s setup. Data in
Progenetix is manually curated. The collection strategies are:
N literature mining using complex search parameters through
PubMed
N identification of called aCGH data, in GP annotation or
tabular format (article, supplementary tables)
N evaluation of supplementary files for probe specific data tables
N follow-up on article links outs, to repository entries or
referenced datasets
User submission. User submitted data was provided in a
number of formats which were converted to the standard format as
described. Although we accept and support private datasets, we
insist on integration of at least the genomic and core clinical data
(e.g. disease classifiers) upon publication of the datasets analysis
results.
Dataset Analysis
Probe remapping. A pipeline has been generated for
determining the genomic positions for the tens to hundreds of
thousands array probes with reference to a common genome
Golden Path edition. For each array platform, the genome
positions of probes were remapped to the current commonly used
version of the human reference genome assembly (NCBI Build
36.1/hg18). Specific mapping procedures were employed for
different types of probes. BAC clones were firstly remapped
according to the clone sets information of Sanger/DECIPHER
database [44]. If the probe position was not available, the UCSC
Genome annotation database [36] (release hg18) was used for
compensation. After these two steps, a mean of 98% of the BAC
clones were remapped. For IMAGE clone sets, only the UCSC
Genome annotation database was used. The average remapping
rate of IMAGE clones was 91%. Affymetrix raw CEL data files
were analyzed based on hg18 library files, namely the output
segments have hg18 coordinates. The summary of the percentage
of mapped probes is given in Table 3. The mapping details for
each platform can be found in the (Table S4).
Probe signal normalization. The array data available was
given in a variety of formats, most frequently as log2 ratio of probe
hybridization intensity. In order to make data from different
platforms directly comparable, all other types of normalized values
were converted to log2. For dye swap experiments, reference/
tumor intensity ratios data was ‘‘reversed’’ representing a tumor/
reference value. For some two-color arrays for which only raw
signal intensity were provided, the normalized log2 ratio for each
probe was calculated by.
r~ log 2 Ts{Tbð Þ=Rs{Rbð Þ:
where Ts and Tb represent tumor sample intensity and tumor
channel background intensity respectively, and Rs and Rb
represent reference sample intensity and reference channel
background intensity respectively. If multiple instances of the
same clone exist, the average signal intensity of the certain clone
was considered.
To call gains and losses according to normalized log2 ratio is an
important step to identify copy number imbalances. For each re-
analyzable dataset, related publications were explored to obtain
original threshold descriptions. If this information was not
available, empirical thresholds were assigned and resulting CNA
calls were visually compared with probe value plots. Processing
method and threshold information for each array are provided in
the Table S5.
Affymetrix genotyping arrays. For the widely used Affy-
metrix GenomeWide SNP arrays, raw CEL files were downloaded
and underwent a massive re-analysis using the R package
aroma.affymetrix [45] with the CRMAv.2 method [46]. During
the processing step, approximately 50 normal sample arrays were
employed as a reference set for each array type to reduce the noise
level. Normal tissue arrays from different labs were extracted and
used to build the reference dataset. In order to obtain high quality
arrays, we excluded arrays which contain segments greater than 3
mega-bases, since copy number variations are always smaller than
3 mega-bases. The list of normal tissue reference arrays is giving in
Table S6.
Quality control. In our review of array data deposited in
GEO or collected from publication supplements we encountered a
large number of individual data sets with insufficient or limited
probe quality. Also, for samples of unprocessed raw data (e.g.
Affymetrix CEL files), we found that QC measures reported
previously (e.g. call rate [47], NUSE [48], RLE [48]) only had a
limited accuracy for detection of arrays with inadequate probe
level data. Currently, the most viable strategy for quality
assessment of processed, heterogeneous copy number arrays is
the visual inspection of probe plotting and segmentation results
through an experienced researcher. For the first arrayMap edition
we generated a quality classification system, which contains a total
of 4 categories based on inspections of genome-wide array plots:
N Excellent. Probe signal distribution is significantly different
between normal regions and imbalance regions. Signal
baseline is distinct and unique, making segmentation threshold
realistic appearing. Chromosomal changes are pretty clear.
N Good. In general good quality. Probe signal may contain some
noise, but tolerable. Chromosomal changes are distinguish-
able.
Table 3. Percentage of remapped probes according to platform types.
Platform type Average mapping rate Number of arrays Number of GPLs
Original HG18 (Build 36) NA 1583 40
in situ oligonucleotide 99% 21678 55
BAC/P1 98% 5464 55
spotted DNA/cDNA 91% 2365 82
doi:10.1371/journal.pone.0036944.t003
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N Hypersegmented. Serrated distribution of probe signal inten-
sities, causing dozens of separate peaks and discontinuous
segments. Chromosomal changes are always up to several
hundreds and smaller than 5 mega-bases.
N Noisy. Probe signal intensities are highly scattered, but well-
distributed, with high standard deviation, resulting in the
inability to differentiate copy number changes.
Depending on the intended research purpose this basic
classification system can be used for a pre-analysis triage of copy
number data. Applying stringent review criteria we identified a
core dataset with ‘‘excellent’’ quality arrays accounting for
approximately 60 percent of total arrays. We are currently
working on a platform independent quality assessment system for
genomic arrays, which will be implemented in future versions of
the arrayMap resource.
Associated data. For arrayMap, data is stored with separate
datasets for each array. This is in contrast to the Progenetix
database, for which technical replicates where available are
combined into case specific CNA profiles. In arrayMap, technical
replicates are assigned an identical case identifier to facilitate
downstream statistical procedures including e.g. clinical data
correlations. The assignment of the correct diagnostic entity to
each sample is an essential step in generating a binding between
genomic and associated data points. At the same time, to ensure
annotation consistency and make the retrieval process more
efficient, for all CNA profiles the following data points were
manually collected from GEO/ArrayExpress and published
papers if available.
N Descriptive diagnostic text, as available through the original
source
N Diagnostic classification according to the International Clas-
sification of Diseases in Oncology (ICDO 3, morphology with
code)
N Tumor locus according to ICD (ICD topography with code)
N Source of material (e.g. primary tumor, cell line, metastasis)
N Clinical parameters where available, including age, gender,
grade, clinical stage (TNM coded), recurrence/progression,
time to recurrence/progression, death and followup
Web Server. An online interface of arrayMap database was
created using Perl common gateway interface (CGI) and R scripts
running on Mac OS X Server. Sample and series data is stored
using a MongoDB database eingine (http://www.mongodb.org).
Precomputed array plots are stored as flat files, mostly in both
SVG and PNG versions. The online release of the service has been
optimized to be compatible with major browsers supporting
current web standards (CSS2, HTML5, XML with inline SVG;
e.g. Safari .=3.0, Firefox .=3.0, InternetExplorer .=9,
Google Chrome) with limited fallback support. Dynamic graphics
provided in the array plot module were implemented as server side
services by technologies including XML/XHTML, JavaScript,
SVG and HTML5 Canvas.
For the future, we intend a quarterly database content revision
to ensure inclusion of newly published articles and GEO/AE
entries. Archived versions of the sample annotations will be made
available upon special request. Additional feature and small data
updates will be performed as seen necessary. The ‘‘News’’ page of
Progenetix/arrayMap will be used for feature and content
announcements.
Supporting Information
Figure S1 Array data sets visualization. Original plots and
optimized parameters for GSE21530 which contains 8 intimal
sarcoma samples hybridized on Agilent CGH Microarray 244A
platform. The normalized probe signal log2 ratios and post-
thresholding segmentation results for each array are intuitively
displayed. Genomic alterations are represented by horizontal
green (gain) and red (loss) lines. Alterations defined here as regions
with log2 ratio .0.15 or ,20.15. Simplified schemas of CNAs
link to UCSC genome browser for further review.
(PDF)
Figure S2 Screenshot of single array visualization.
ArrayMap plots for GSM630977 (acute myelogenous leukemia).
Besides the whole genome view, subviews of each chromosome are
displayed as well. From these plots, different kinds of genetic
variation events are clearly revealed, e.g. massive genomic
rearrangement in chromosome 6; arm-level gain of chromosome
8q and 3MB focal change around 1p31.3. Through the ‘‘Plot
Array Data’’ interface, users can segment the raw data values and
re-plot the results with customized parameters.
(PDF)
Figure S3 Plot single genomic region. In the ‘‘Plot Array
Data’’ interface, input the precise location (chr5:1100000-
1400000) in ‘‘Plot Region’’ field. Plots with this region were
generated for all 8 arrays in the current series (GSE21530). In this
region, there are 5 genes which are shown schematically as colored
boxes. CNA status and copy number transition points for these
genes are displayed.
(PDF)
Figure S4 Compound CNA query. (A) Four gene loci
associated with glioblastoma (EGFR, PTEN, ASPM and
CDKN2A) were inserted into ‘‘Match (Multiple) Regions &
Types’’ field. 303 out of 42421 arrays were returned. (B)
Classification information of these 303 arrays were displayed
and can be selected for the following analysis. (C) Statistical and
plot parameters can be customized. Associated data was processed
by online tools, and returned results included: (D) Chromosomal
ideogram and (E) histogram, show frequency of copy number
aberrations; (F) Matrix plot reveals the aberration pattern of
selected arrays; (G) Array classification tree generated by
hierarchical Ward clustering, arrays with similar frequency of
CNA are part of the tree branch. (H) Heatmap of CNA
frequencies clustered by clinical group.
(PDF)
Figure S5 Heatmap of frequency profiles for 59 cancer
types. Heatmap visualization of frequency profiles for all ICD-O
entities containing more than 50 arrays in our core dataset. Region
specific gain/loss frequencies were mapped to 1MB intervals. The
intensity of colors (green: gains; losses: red) corresponds to the
relative frequency of CNAs for each interval.
(PDF)
Table S1 Entities extracted from NCBI GEO and EBI
ArrayExpress.
(XLS)
Table S2 Cancer entities grouped by ICD-O code.
(XLS)
Table S3 Platform type distribution in arrayMap.
(XLS)
Table S4 Probe remapping rate for platforms.
(XLS)
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Table S5 Processing method and threshold for calling
genomic gains and losses.
(XLS)
Table S6 Normal tissue reference arrays for Affymetrix
platforms.
(XLS)
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